Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (1385)	2/26/2005 10:40:04 AM
From: Biomaven	Read Replies (2) \| Respond to of 1834

From their 10K Beginning in September 2003, and continuing through December 2004, our costs of marketing and selling Cialis in the United States are fully reimbursable by Lilly ICOS. Thereafter, selling activities using ICOS sales representatives are generally reimbursable by Lilly ICOS at 60% of actual cost. The cost of marketing activities will continue to be fully reimbursed by Lilly ICOS. ... Lilly is currently responsible for all sales and marketing activities for Cialis outside the United States. However, beginning as early as 2006, we are required to assume a portion of the sales and marketing responsibilities for Cialis in Canada, Mexico and five European countries. Starting in 2007, we are required to assume a portion of the sales and marketing responsibilities in all territories where Cialis is sold by Lilly ICOS. As an alternative to deploying a sales force ourselves, we may fulfill our sales and marketing responsibilities in those territories by engaging Lilly or unrelated third parties. Peter